Endogenous metabolites were identified by matching the MS and MS/MS fragmentation information against the KEGG (https://www.genome.jp/kegg/) and HMDB (http://www.hmdb.ca/) databases. MetaboAnalyst 5.0 was used to analyze metabolite changes following QJSB treatment, and metabolic pathway impact values > 0.1 were considered statistically significant.
"],"repository":["MetaboLights"],"study_status":["Public"],"ptm_modification":[""],"instrument_platform":["Liquid Chromatography MS - alternating - reverse-phase"],"chromatography_protocol":["Metabolomic analysis was performed using a UHPLC-Q-Exactive Plus Orbitrap-MS system (Thermo Fisher Scientific, USA) equipped with a ZORBAX Eclipse Plus C18 column (2.1 × 100 mm, 1.8 μm; Agilent Technologies, USA). The mobile phase consisted of water (0.1% formic acid, A) and acetonitrile (0.1% formic acid, B), with the following gradient elution: 0–2.5 min, 2% B; 2.5–5 min, 2–40% B; 5–12 min, 40–100% B; 12–16 min, 100% B; 16–16.1 min, 100–2% B; 16.1–19 min, 2% B, at a flow rate of 0.3 mL/min. The ion spray voltages were set to 3.5 kV (positive) and 2.8 kV (negative), with a mass scan range of m/z 100–1500. The sheath gas heater temperature and capillary temperature were maintained at 350°C and 320°C, respectively.
"],"publication":["Qijiao Shengbai capsule ameliorates ulcerative colitis in mice by modulating gut microbiota and protecting the intestinal barrier, associated with suppression of the TLR4/MyD88/NF-κB Pathway."],"submitter_name":["Yi Lu"],"submitter_affiliation":["Guizhou Medical University"],"organism_part":["colon"],"technology_type":["mass spectrometry assay"],"disease":[""],"extraction_protocol":["The supernatants from all samples were filtered through a 0.22-μm membrane filter and transferred to sample vials for subsequent analysis. In addition, quality control (QC) samples for method validation were prepared by pooling 5-μL aliquots of each fecal or colon tissue supernatant.
"],"organism":["Mus musculus"],"full_dataset_link":["https://www.ebi.ac.uk/metabolights/MTBLS14943"],"author":["Yi Lu. Guizhou Medical University. 17311987664@163.com.","Xiuli Gao. Guizhou Medical University. gaoxl@gmc.edu.cn."],"data_transformation_protocol":["The dynamic exclusion duration was 3 s, and the S-lens RF level was set to 50. Mass spectrometry data were preprocessed using Compound Discoverer 3.2 software (Thermo Fisher Scientific, USA) for peak identification, alignment, and retention time correction. Principal component analysis (PCA) and orthogonal partial least-squares discriminant analysis (OPLS-DA) were performed using SIMCA-P 14.1 software (Umetrics, AB, Sweden).
"],"study_factor":["Treatment"],"submitter_email":["17311987664@163.com"],"sample_collection_protocol":["Colon tissue samples (100 mg) were homogenized under low-temperature conditions and mixed with 500 μL of pre-chilled methanol–acetonitrile–water (1:1:1, v/v/v). After vortexing for 1 min and ultrasonic extraction on ice for 15 min, the homogenates were kept at –20°C overnight and then centrifuged.
"],"omics_type":["Metabolomics"],"study_design":["Qijiao Shengbai capsule","Thermo Scientific Vanquish UHPLC System","Metabolomics","intestinal barrier","untargeted analysis","TLR4/MyD88/NF-κB pathway","colon","ulcerative colitis","Mus musculus","Q Exactive Plus","gut microbiota","experimental sample"],"curator_keywords":["Qijiao Shengbai capsule","Thermo Scientific Vanquish UHPLC System","Metabolomics","untargeted analysis","intestinal barrier","TLR4/MyD88/NF-κB pathway","colon","ulcerative colitis","Mus musculus","Q Exactive Plus","gut microbiota","experimental sample"],"mass_spectrometry_protocol":["Metabolomic analysis was performed using a UHPLC-Q-Exactive Plus Orbitrap-MS system (Thermo Fisher Scientific, USA) equipped with a ZORBAX Eclipse Plus C18 column (2.1 × 100 mm, 1.8 μm; Agilent Technologies, USA). The mobile phase consisted of water (0.1% formic acid, A) and acetonitrile (0.1% formic acid, B), with the following gradient elution: 0–2.5 min, 2% B; 2.5–5 min, 2–40% B; 5–12 min, 40–100% B; 12–16 min, 100% B; 16–16.1 min, 100–2% B; 16.1–19 min, 2% B, at a flow rate of 0.3 mL/min. The ion spray voltages were set to 3.5 kV (positive) and 2.8 kV (negative), with a mass scan range of m/z 100–1500. The sheath gas heater temperature and capillary temperature were maintained at 350°C and 320°C, respectively.
"],"additional_accession":[]},"is_claimable":false,"name":"Qijiao Shengbai capsule ameliorates ulcerative colitis in mice by modulating gut microbiota and protecting the intestinal barrier, associated with suppression of the TLR4/MyD88/NF-κB Pathway","description":"Background: Qijiao Shengbai capsule (QJSB) is a classic traditional Chinese compound formulation composed of seven herbal ingredients, primarily used clinically to treat leukopenia. Individual herbs and their active components within QJSB demonstrate favorable efficacy against ulcerative colitis (UC). Nevertheless, no evidence exists of QJSB being a full-form prescription for treating UC.
Methods: This study identified the chemical composition of QJSB using UHPLC-ESI-Q-Exactive Plus Orbitrap-MS. At the same time, a mouse model of ulcerative colitis (UC) was established using DSS to examine the effects of QJSB on disease symptoms, inflammatory factors, intestinal barrier function, and colonic histopathological changes. Furthermore, metabolomics, 16S rRNA sequencing, and network pharmacology were combined to analyze the potential mechanisms underlying the effects of QJSB intervention in UC-affected mice, and key pathways predicted by network pharmacology were validated using Western blot analysis.
Results: The results showed that QJSB treatment significantly alleviated DSS-induced colitis symptoms in UC mice, as evidenced by weight recovery, a decrease in the disease activity index (DAI), improvement in colonic shortening, and reduced tissue damage. Gut microbiota analysis indicated that QJSB modulates the composition of the gut microbiota by upregulating the abundance of Akkermansia and Lactobacillus and downregulating the abundance of Bacteroides. Metabolomics results suggest that QJSB may help correct metabolic disturbances involving amino acids, linoleic acid, arachidonic acid, and alpha-linolenic acid. Furthermore, QJSB was associated with reduced levels of pro-inflammatory factors (TNF-α, IL-6, IL-1β), lipopolysaccharide (LPS), and myeloperoxidase (MPO), as well as improved intestinal barrier function. Western blot results suggest that QJSB intervention may be associated with the suppression of TLR4/MyD88/NF-κB signaling pathway activation.
Conclusion: The present findings suggest that QJSB may exert therapeutic effects against UC, potentially through mechanisms involving the inhibition of inflammatory responses, protection of intestinal barrier function, regulation of metabolic homeostasis, and restoration of gut microbial ecology. These results imply that QJSB could serve as a potential therapeutic candidate for UC and provide a new basis for its clinical application.
","dates":{"publication":"2026-09-08","submission":"2026-07-04"},"accession":"MTBLS14943","cross_references":{}}